Multi-disciplinary team meetings for lung cancer in Norway and Denmark: results from national surveys and observations with MDT-MODe
We found similar organization of MDT meetings in both countries, with the main difference being more local MDT meetings in Norway. All lung cancer MDTs were chaired by respiratory physicians and attended by a radiologist. Other members included oncologists, pathologists, thoracic surgeons, specialist nurses, nuclear medicine specialists and junior doctors. Overall, members reported that they had sufficient time for preparation and attending MDT meetings. With the MDT-MODe instrument it was found that the MDT chairs, surgeons, oncologists, radiologists all contributed positively to case discussion. Comorbidities were included in the discussion of most patients while the patient's view and psychosocial issues were less often discussed. A treatment decision was reached in 79.7% of cases discussed. In conclusion, we found similar settings and overall good quality concerning lung cancer MDT meetings in Denmark and Norway.
Authors
- Kirill Neumann (ORCID: https://orcid.org/0009-0007-2513-0871)
- Christina Aamelfot
- Anja Gouliaev (ORCID: https://orcid.org/0000-0002-6161-5936)
- Torben Riis Rasmussen (ORCID: https://orcid.org/0000-0002-7030-9260)
- Arman Arshad (ORCID: https://orcid.org/0000-0002-6666-3873)
- Janna Berg (ORCID: https://orcid.org/0000-0002-4392-2289)
- Niels Lyhne Christensen (ORCID: https://orcid.org/0000-0002-7236-5856)
- Håkon Olav Leira (ORCID: https://orcid.org/0000-0003-0845-3891)
- Rana Bibi
Institutions
- Aarhus University (DK)
- Aalborg University Hospital (DK)
- Akershus University Hospital (NO)
- Haukeland University Hospital (NO)
- Odense University Hospital (DK)
- Sykehuset i Vestfold (NO)
- Aarhus University Hospital (DK)
- St Olav's University Hospital (NO)
Publication Details
- Journal
- Acta Oncologica
- Published
- 2024-08-11
- DOI
- https://doi.org/10.2340/1651-226x.2024.40777
- Citations
- 4
- Primary Topic
- Clinical practice guidelines implementation
- Type
- article
- Field-Weighted Citation Impact
- 2.17
Funders
- AstraZeneca